1. Receptor binding and escape from beta antibody responses drive omicron-B.1.1.529 evolution;Zahradník;bioRxiv,2021
2. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial;Stuart;Lancet,2021
3. SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection;Cele;medRxiv,2021
4. SARS-CoV-2 B.1.1.529 variant (omicron) evades neutralization by sera from vaccinated and convalescent individuals;Roessler;medRxiv,2021
5. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies;Wilhelm;medRxiv,2021